Get the Weekly Intelligence Brief — top committee picks every Sunday.
ARGX · NASDAQ · STOCK

argenx SE

Healthcare Updated August 11, 2026
$864.40
52W $636.10 – $953.58
69/100
$53.78B
31.3
-0.02
AI Committee Verdict
Buy
69/100
Conviction: Moderate · 67% agreement · 6 analysts
Moderate

Is ARGX Bullish or Bearish?

Bullish. Innellis AI committee rates argenx SE (ARGX) Buy with a composite score of 69/100 , based on 6 analysts with 67% agreement. Last updated August 11, 2026.

What Would Change This View

Upgrade to Strong Buy
Requires a committee score of 75.0 — +5.60 from today. Applies on the first day at or above the line; upgrades are never dampened.
Downgrade to Watch
Requires the score to fall below 55.0 — -14.40 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.

Executive Summary

The primary driver is revenue growing 71.3% yoy -- genuine top-line momentum. The main limiting factor is price-to-book of 6.9x prices in significant intangible value. The committee is constructive but not yet at full conviction.

Bull & Bear Case

Bull Case
  • ROE of 22.4% shows genuine earnings power backing the valuation — Value
  • Revenue growing 71.3% YoY -- genuine top-line momentum — Growth
  • EPS growing 95.7% YoY — Growth
  • Low leverage (debt-to-equity 0.01) -- balance sheet can absorb a shock — Risk
  • VIX regime is low -- calm backdrop supports risk-taking — Macro
  • Market regime is bullish (Bull market -- normal position sizing) — Macro
Bear Case
  • Price-to-book of 6.9x prices in significant intangible value — Value
  • MACD histogram negative -- bearish momentum — Technical
Both cases are generated from quantitative data signals, not qualitative or forward-looking judgement. They summarise what the numbers say today.
Price History (6M)

AI Investment Committee

Committee Consensus As of August 11, 2026
Overall Committee Score
69/100
Agreement
67%
Analysts
6
Conviction
Moderate
Sector Rank
Top 4%
of 192 Healthcare peers
Value Analyst neutral
59 / 100 · High confidence
Fair value -- neither a bargain nor obviously overpriced
+ ROE of 22.4% shows genuine earnings power backing the valuation
− Price-to-book of 6.9x prices in significant intangible value
Growth Analyst bullish
85 / 100 · Moderate confidence
Strong, accelerating growth with consistent execution
+ Revenue growing 71.3% YoY -- genuine top-line momentum
Technical Analyst neutral
48 / 100 · High confidence
Mixed or range-bound price action
− MACD histogram negative -- bearish momentum
Risk Analyst bullish
80 / 100 · Low confidence
Risk profile is manageable -- leverage, volatility, and event exposure all look contained
+ Low leverage (debt-to-equity 0.01) -- balance sheet can absorb a shock
Macro Analyst bullish
78 / 100 · Moderate confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
+ VIX regime is low -- calm backdrop supports risk-taking
News Analyst bullish
67 / 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+0.29 across 7 articles, 14d)
Portfolio Manager neutral
55 / 100 · Moderate confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− 2 existing position pair(s) are highly correlated already
Open Full Terminal →

Technical Analysis

RSI (14)
47.9
Neutral
MACD Histogram
-1.025
Bearish Momentum
Trend Direction
Sideways
Weekly: Uptrend
Market Structure
Mixed
Support
$771.39
Resistance
$880.28
Bollinger %B
0.45
Inside Bands
Price vs Moving Averages
EMA 9
$865.57 Below
EMA 21
$870.35 Below
EMA 50
$864.80 Below
EMA 200
$813.55 Above

Fundamental Analysis

Valuation
53
Profitability
97
Financial Health
100
Cash Flow
70
Valuation
P/E Ratio 31.3×
P/B Ratio 6.39×
PEG Ratio 0.09
Dividend Yield 0.00%
52W High $953.58
52W Low $636.10
Quality & Growth
ROE 1764.3%
ROA 1488.1%
Gross Margin 8994.2%
Operating Margin 2880.6%
Revenue Growth YoY
Debt / Equity 0.01
AI Fundamental Assessment
[reduced confidence: limited earnings history] P/E ratio of 31.3 (rich relative to a 15-40x range); Price-to-book of 6.4x; PEG ratio of 0.1 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 17.6%; Return on assets of 14.9%; Net margin of 32.9%; Gross margin of 89.9%; Current ratio of 5.12 (healthy short-term liquidity); Debt-to-equity of 0.01; Free cash flow per share is positive (18.00); Earnings-history trend unavailable; growth based on TTM year-over-year only.
Get the Full ARGX Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →

Explore ARGX Further

📈 Rating History 💰 Earnings 📰 Recent Events 🔄 What Changed 📖 Thesis Evolution 🔍 Similar Stocks
Weekly Intelligence Brief
Get the committee's top-scored stocks every Sunday.
Free · No spam · Unsubscribe anytime